MCID: ENT004
MIFTS: 51

Enthesopathy

Categories: Bone diseases, Muscle diseases

Aliases & Classifications for Enthesopathy

MalaCards integrated aliases for Enthesopathy:

Name: Enthesopathy 12 44 15 17 70
Rheumatism 70

Classifications:



External Ids:

Disease Ontology 12 DOID:204
ICD9CM 34 726.90
MeSH 44 D000070676
SNOMED-CT 67 278525009
ICD10 32 M77.9 M79.0
UMLS 70 C0035435 C0242490

Summaries for Enthesopathy

Disease Ontology : 12 A connective tissue disease characterized by damage of tissues located in the entheses, the site of insertion of tendons or ligaments into bones or joint capsules, with symptoms of pain, swelling and inflammation.

MalaCards based summary : Enthesopathy, also known as rheumatism, is related to pustulosis of palm and sole and spondylitis, and has symptoms including myalgia, joint symptom and musculoskeletal symptom. An important gene associated with Enthesopathy is PHEX (Phosphate Regulating Endopeptidase Homolog X-Linked), and among its related pathways/superpathways are Parathyroid hormone synthesis, secretion and action and Endochondral Ossification. The drugs Ixekizumab and Sulfasalazine have been mentioned in the context of this disorder. Affiliated tissues include entheses, skin and bone, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 73 An enthesopathy refers to a disorder involving the attachment of a tendon or ligament to a bone. This... more...

Related Diseases for Enthesopathy

Diseases related to Enthesopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
# Related Disease Score Top Affiliating Genes
1 pustulosis of palm and sole 31.0 TNF CRP CCR6
2 spondylitis 30.8 TNF ERAP1 CRP CCR6
3 reactive arthritis 30.5 TNF CRP CCR6
4 brucellosis 30.4 TNF MEFV CRP
5 bursitis 30.4 TNF LAPTM4A CRP
6 familial mediterranean fever 30.4 TNF MEFV CRP
7 plantar fasciitis 30.3 LAPTM4A CRP
8 epicondylitis 30.3 LAPTM4A ACAN
9 osteomyelitis 30.2 TNF MEFV CRP
10 hyperostosis 30.2 KL GALNT3 FGF23 ANKH
11 arthropathy 30.2 TNF CRP ANKH ACAN
12 synovitis 30.1 TNF CRP ACAN
13 juvenile ankylosing spondylitis 30.1 TNF MEFV ERAP1
14 ankylosis 30.1 TNF ENPP1 CCR6 ANKH
15 hypophosphatemic rickets, x-linked recessive 30.1 SLC34A3 PHEX MEPE FGF23 ENPP1
16 periarthritis 30.0 MEFV ENPP1 ANKH
17 tenosynovitis 30.0 TNF CRP
18 chronic recurrent multifocal osteomyelitis 30.0 TNF MEFV CRP
19 dysentery 30.0 TNF CRP CCR6
20 temporal arteritis 29.9 TNF CRP CCR6
21 spondyloarthropathy 1 29.7 TNF PTH ERAP1 CRP CCR6 ANKH
22 bone inflammation disease 29.7 TNF CRP CCR6 ACAN
23 chondromalacia 29.7 TNF CRP ACAN
24 iritis 29.7 TNF ERAP1 CRP CCR6
25 vitamin d-dependent rickets 29.6 PTH PHEX
26 celiac disease 1 29.3 TNF PTH CRP CCR6
27 osteomalacia 29.2 SLC34A3 PTH PHEX MEPE FGF23 ENPP1
28 rickets 29.2 SLC34A3 PTH PHEX MEPE KL FGF23
29 hypophosphatemia 29.2 SLC34A3 PTH PHEX MEPE KL FGF23
30 arthritis 28.8 TNF PTH MEFV CRP CCR6 ANKH
31 arterial calcification of infancy 28.6 SLC34A3 PHEX KL GALNT3 FGF23 ENPP1
32 hypophosphatemic rickets, x-linked dominant 28.5 SLC34A3 PTH PHEX MEPE KL GALNT3
33 autosomal recessive hypophosphatemic rickets 28.2 SLC34A3 PTH PHEX MEPE KL GALNT3
34 bone disease 28.0 TNF SLC34A3 PTH PHEX FGF23 CCR6
35 diffuse idiopathic skeletal hyperostosis 11.0
36 hereditary hypophosphatemic rickets 10.9
37 inflammatory spondylopathy 10.5
38 psoriatic arthritis 10.4
39 spondyloarthropathy 10.4
40 psoriasis 10.4
41 opsismodysplasia 10.4 PHEX FGF23
42 ankylosing spondylitis 1 10.4 FGF23 CRP
43 tendinitis 10.4
44 suppurative lymphadenitis 10.4 CRP CCR6
45 amyloidosis aa 10.4 MEFV CRP
46 drug reaction with eosinophilia and systemic symptoms 10.4 TNF CRP
47 suppurative periapical periodontitis 10.4 PHEX CRP
48 hereditary periodic fever syndrome 10.3 TNF MEFV
49 anterior scleritis 10.3 TNF CRP
50 rheumatoid arthritis interstitial lung disease 10.3 TNF CRP

Comorbidity relations with Enthesopathy via Phenotypic Disease Network (PDN):


Acute Cystitis Hypertension, Essential

Graphical network of the top 20 diseases related to Enthesopathy:



Diseases related to Enthesopathy

Symptoms & Phenotypes for Enthesopathy

UMLS symptoms related to Enthesopathy:


myalgia; joint symptom; musculoskeletal symptom

MGI Mouse Phenotypes related to Enthesopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.17 ANKH CRP ENPP1 ERAP1 FGF23 GALNT3
2 homeostasis/metabolism MP:0005376 10.17 ANKH CCR6 CRP EMP1 ENPP1 FGF23
3 hematopoietic system MP:0005397 10.11 ANKH CCR6 ERAP1 FGF23 GALNT3 KL
4 immune system MP:0005387 10.07 ANKH CCR6 CRP ENPP1 ERAP1 FGF23
5 craniofacial MP:0005382 9.95 ANKH ENPP1 GALNT3 KL PHEX PTH
6 limbs/digits/tail MP:0005371 9.81 ANKH ENPP1 FGF23 GALNT3 KL LAPTM4A
7 renal/urinary system MP:0005367 9.5 ENPP1 ERAP1 FGF23 GALNT3 KL PHEX
8 skeleton MP:0005390 9.44 ANKH ENPP1 ERAP1 FGF23 GALNT3 KL

Drugs & Therapeutics for Enthesopathy

Drugs for Enthesopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
2
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
3
Colchicine Approved Phase 4 64-86-8 6167 2833
4
Febuxostat Approved Phase 4 144060-53-7 134018
5
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
6
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
7
Etanercept Approved, Investigational Phase 4 185243-69-0
8
Hydroxychloroquine Approved Phase 4 118-42-3 3652
9
Ravulizumab Approved, Investigational Phase 4 1803171-55-2
10
Protein C Approved Phase 4
11
Tofacitinib Approved, Investigational Phase 4 477600-75-2
12
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
13
Abatacept Approved Phase 4 332348-12-6 10237
14
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
15
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
16
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
19
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
21
Uric acid Investigational Phase 4 69-93-2 1175
22 Hematinics Phase 4
23 Antimitotic Agents Phase 4
24 Diacetylrhein Phase 4
25 Tubulin Modulators Phase 4
26 Hydrocortisone 17-butyrate 21-propionate Phase 4
27 Hydrocortisone hemisuccinate Phase 4
28 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
29 Immunoglobulins Phase 4
30 Antibodies Phase 4
31 Antibodies, Monoclonal Phase 4
32 Gastrointestinal Agents Phase 4
33 Antiparasitic Agents Phase 4
34 Anti-Bacterial Agents Phase 4
35 Antimalarials Phase 4
36 Antiprotozoal Agents Phase 4
37 Anti-Infective Agents Phase 4
38 Complement System Proteins Phase 4
39 Angiogenesis Inhibitors Phase 4
40 Pharmaceutical Solutions Phase 4
41 Vaccines Phase 4
42 Folic Acid Antagonists Phase 4
43 Vitamin B9 Phase 4
44 Immunosuppressive Agents Phase 4
45 Vitamin B Complex Phase 4
46 Immunologic Factors Phase 4
47 Folate Phase 4
48 Antimetabolites Phase 4
49 Dermatologic Agents Phase 4
50 Anti-Inflammatory Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 298)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy Completed NCT00420303 Phase 4 Etanercept
3 Comparison of Combination Disease Modifying Antirheumatic Drugs (DMARDs) With Single Drug (Methotrexate) Therapy in Early Rheumatoid Arthritis Completed NCT02644499 Phase 4 Methotrexate;Leflunomide;Hydroxychloroquine;Prednisolone;Folic Acid
4 Diacerein Combined With Febuxostat Relieves Symptoms of Gout by Suppressing IL-1βinflammation Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
5 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
6 Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17, Demonstration of Double-blind Trial Results Completed NCT03558971 Phase 4 Cortisol
7 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Completed NCT03762824 Phase 4
8 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
9 Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar® Completed NCT00828997 Phase 4
10 A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive Completed NCT03151551 Phase 4 Ixekizumab;Adalimumab
11 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Recruiting NCT04390464 Phase 4 Ravulizumab;Baricitinib
12 Immunogenicity and Safety of the CoronaVac Vacccine in Patients With Autoimmune Rheumatic Diseases and People Living With HIV/AIDS Recruiting NCT04754698 Phase 4
13 Capability of Tofacitinib or Etanercept to Accelerate Clinical Relevant Tapering of Non-steroidal Anti-inflammatory Drugs (NSAID) and Treat-to-target Guided De-escalation of Corticosteroids in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Previous csDMARD Therapy (AcceleRAte) Recruiting NCT04485325 Phase 4 Tofacitinib
14 Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
15 EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA) Not yet recruiting NCT03669367 Phase 4 Abatacept Injection;hydroxycloroquina
16 Safety and Immunogenicity of a Recombinant Subunit Herpes Zoster Vaccine in Patients With Rheumatic Diseases Undergoing Immunosuppressive or Biologic/Targeted DMARD Therapies: a Double-blind Randomized Placebo-controlled Trial Not yet recruiting NCT04748939 Phase 4
17 Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure Terminated NCT01823393 Phase 4 Heparin;NaCl
18 A Study to Evaluate the Clinical Benefits of Tramadol/Acetaminophen (Ultracet®) vs. Diclofenac (Voltaren®) in the Treatment of Pain in Patients With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs) Terminated NCT00766402 Phase 4 Tramadol /acetaminophen;Diclofenac
19 Randomized, Phase IV, Placebo-controlled, Comparative Study to Evaluate the Efficacy and Safety of Tapering Methotrexate (MTX) Dosage Versus Maintaining the Dosage in Patients With Severe Active Rheumatoid Arthritis (RA) Who Have Demonstrated an Inadequate Response (IR) to Prior Disease-modifying Anti-rheumatic Drugs (DMARDs) Treatment and Have Initiated RoActemra (RoActemra, TCZ) in Combination With MTX Terminated NCT01661140 Phase 4 Methotrexate (stable dose);Tocilizumab;Methotrexate (tapering dose)
20 Treatment for Achilles Tendinopathy Unknown status NCT00835939 Phase 2, Phase 3 25% Dextrose and 1% Lidocaine;Lidocaine
21 Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir of Chinese HIV/AIDS Patients In Acute HIV-1 Infection Unknown status NCT02219672 Phase 3 Triplitode;Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir
22 Efficiency of Radiofrequency Ablation for Surgical Treatment of Chronic Atrial Fibrillation With Rheumatic Valve Disease Unknown status NCT01013688 Phase 3
23 Phase III Study Comparing Association of Anti-inflammatory and Anti-rheumatic Unknown status NCT02448199 Phase 3 Meloxicam and Glucosamine;Meloxicam;Glucosamine
24 Multicenter Comparative Randomised Double-blind Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line of Biological Therapy of Patients With Active Rheumatoid Arthritis Completed NCT02744196 Phase 3 Placebo;Methotrexate
25 DOES ETANERCEPT INFLUENCE TWEAK MODULATION OF INFLAMMATION DURING INFLAMMATORY RHEUMATISMS (PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS)? Completed NCT02164214 Phase 3 etanercept Treatment
26 A Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis Completed NCT01166282 Phase 3
27 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy in the Treatment of Enthesitis at the Achilles Tendon up to 1 Year in Adult Patients With Active Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA) (ACHILLES) Completed NCT02771210 Phase 3 Secukinumab Placebo
28 A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis Completed NCT03031782 Phase 3 AIN457
29 Long-term Extension Study of Safety During Treatment With Tocilizumab (MRA) in Patients Completing Treatment in MRA Core Studies Completed NCT00720798 Phase 3 Tocilizumab;Disease-modifying anti-rheumatic drugs;Non-steroidal anti-inflammatory drugs;Oral corticosteroids
30 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis Completed NCT01721057 Phase 3 Placebo;Baricitinib;cDMARD
31 Sun Yat-sen University Cancer Center Completed NCT03674294 Phase 3 Aprepitant;Palonosetron;Dexamethasone;Placebo Oral Tablet
32 Comparison of Sulfasalazine Versus Leflunomide Based Combination Disease Modifying Anti-rheumatic Drug Therapy (DMARD) in Patients With Rheumatoid Arthritis Failing Methotrexate Monotherapy : A Randomized Control Trial Completed NCT02930343 Phase 3 Methotrexate;Leflunomide;Hydroxychloroquine;Prednisolone;Folic Acid;Sulfasalazine
33 A Randomized Trial of Pocket-Echocardiography Integrated Mobile Health Device Assessments in Modern Structural Heart Disease Clinics Completed NCT02881398 Phase 2, Phase 3
34 A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment Completed NCT02873936 Phase 3 Filgotinib;Placebo to match filgotinib;csDMARDs
35 A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed NCT01232569 Phase 3 Tocilizumab 162 mg;Placebo
36 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O) Completed NCT01202760 Phase 3 LY2127399;Placebo
37 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy Completed NCT00646178 Phase 3 adalimumab;placebo for adalimumab
38 A Randomized, Double-blind, Parallel Group Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed NCT01194414 Phase 3 tocilizumab SC;tocilizumab IV;placebo to tocilizumab SC;placebo to tocilizumab IV;Disease-modifying antirheumatic drugs (DMARDs)
39 Assessment of the Early Efficacy Response Rate of Leflunomide According to the Initial Dosing Regimen in the Treatment of Naive-DMARD (Disease Modifying Anti-Rheumatic Drug) Early RA (Rheumatoid Arthritis)-Patients Completed NCT00596206 Phase 3 leflunomide
40 Randomized Placebo-controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-modifying Anti-rheumatic Drugs (DMARDs) in Patients... Completed NCT00810199 Phase 3 tocilizumab [RoActemra/Actemra];methotrexate;placebo
41 An Open-label, Prospective, Multi-Centre Study to Assess the Safety and Efficacy of Adalimumab (Humira®) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis Completed NCT01231321 Phase 3 adalimumab
42 An Open Label Study of the Safety During Treatment With Tocilizumab (TCZ), in Combination With Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Rheumatoid Arthritis Completed NCT01214733 Phase 3 tocilizumab [RoActemra/Actemra]
43 Open-Label, Phase IIIb Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab Monotherapy or Combination Therapy With Methotrexate (MTX) or Other Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Patients With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-Tumour Necrosis Factor (Anti-TNF) Biologic Agent Completed NCT02046603 Phase 3 Tocilizumab;DMARDs;Oral Corticosteroids;Methotrexate
44 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) Completed NCT02955212 Phase 3 Upadacitinib;Placebo
45 An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-α Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis Completed NCT00448383 Phase 3
46 An Open-Label, Prospective Study of the Safety of Rituximab in Combination With Other Disease-Modifying Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis Completed NCT00443651 Phase 3 Rituximab;Anti-inflammatory drugs
47 A Randomized, Double-blind Trial of the Safety of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis on Standard Disease-modifying Anti-Rheumatic Drug Background Therapy. Completed NCT00036387 Phase 3 Infliximab
48 Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
49 A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs (DMARDS) Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy Completed NCT00048581 Phase 3 Abatacept;Placebo;Abatacept
50 An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis Recruiting NCT03769168 Phase 3 AIN457

Search NIH Clinical Center for Enthesopathy

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Angelica sinensis preparation
Antirheumatic Agent [EPC]
Cyclophosphamide
Hydrocortisone
hydrocortisone acetate
HYDROCORTISONE ACETATE PWDR
HYDROCORTISONE ACETONIDE
Hydrocortisone butyrate
hydrocortisone cypionate
hydrocortisone probutate
HYDROCORTISONE PWDR
Hydrocortisone sodium phosphate
Hydrocortisone sodium succinate
hydrocortisone valerate
HYDROCORTISONE,NONSTERILE PWDR
Hydroxychloroquine
Hydroxychloroquine Sulfate
leflunomide
Penicillamine
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR
Triamcinolone
Triamcinolone Acetonide
TRIAMCINOLONE ACETONIDE PWDR
triamcinolone diacetate
triamcinolone hexacetonide

Cochrane evidence based reviews: enthesopathy

Genetic Tests for Enthesopathy

Anatomical Context for Enthesopathy

The Foundational Model of Anatomy Ontology organs/tissues related to Enthesopathy:

19
Entheses

MalaCards organs/tissues related to Enthesopathy:

40
Skin, Bone, Cortex, Eye, Adrenal Cortex, Salivary Gland, Bone Marrow

Publications for Enthesopathy

Articles related to Enthesopathy:

(show top 50) (show all 12319)
# Title Authors PMID Year
1
Systems pharmacology-based dissection of mechanisms of Tibetan medicinal compound Ruteng as an effective treatment for collagen-induced arthritis rats. 61
33610711 2021
2
Standardization of Kaempferia galanga L. rhizome and vasorelaxation effect of its key metabolite ethyl p-methoxycinnamate. 61
33571614 2021
3
Pharmacological and toxicological effects of Ruta chalepensis L. on experimentally induced seizures and electroencephalographic spectral power in mice. 61
33485978 2021
4
Anti-inflammatory activity of Nectandra angustifolia (Laurel Amarillo) ethanolic extract. 61
33609727 2021
5
Ethnomedicinal uses, phytochemistry, and biological activities of plants of the genus Gynura. 61
33465439 2021
6
The anti-inflammatory and analgesic activities of the ethyl acetate extract of Viburnum taitoense Hayata. 61
33359186 2021
7
Uses, chemical compositions, pharmacological activities and toxicology of Clematidis Radix et Rhizome- a Review. 61
33476714 2021
8
Leaves of Cleome amblyocarpa Barr. And Murb. And Cleome arabica L.: Assessment of nutritional composition and chemical profile (LC-ESI-MS/MS), anti-inflammatory and analgesic effects of their extracts. 61
33359854 2021
9
Axial Articular Manifestations in Primary Sjögren Syndrome: Have We Been Missing Spondyloarthritis for All This Time? 61
33795332 2021
10
Isolation and characterization of anti-inflammatory and analgesic compounds from Uapaca staudtii Pax (Phyllanthaceae) stem bark. 61
33359855 2021
11
Cassia sieberiana DC. leaves modulate LPS-induced inflammatory response in THP-1 cells and inhibit eicosanoid-metabolizing enzymes. 61
33359184 2021
12
Sesquiterpene lactones from Lychnophora species: Antinociceptive, anti-inflammatory, and antioxidant pathways to treat acute gout. 61
33359866 2021
13
Raynaud's Phenomenon: A Vascular Acrosyndrome That Requires Long-Term Care. 61
33632387 2021
14
Disease phenotype and diagnostic delay in Saudi patients with primary Sjögren's syndrome: An exploratory cross-sectional study. 61
33795496 2021
15
Imaging of calcific tendinopathy around the shoulder: usual and unusual presentations and common pitfalls. 61
33151457 2021
16
ANCA-associated vasculitis can present with episodic attacks of joint pain consistent with palindromic rheumatism. 61
33795279 2021
17
Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review. 61
33543338 2021
18
Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. 61
33619703 2021
19
[Systemic lupus erythematosus]. 61
33740079 2021
20
'Black and white and every wrong colour': The medical history of Jane Austen and the possibility of systemic lupus erythematosus. 61
33596714 2021
21
Neuropsychiatric involvement in systemic lupus erythematosus: A review. 61
33609799 2021
22
Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults. 61
32841547 2021
23
[Systemic lupus erythematosus]. 61
33512549 2021
24
The spectrum of idiopathic inflammatory myopathies in South Africa. 61
32212001 2021
25
Limited sensitivity and specificity of ACR/EULAR-2019 classification criteria for SLE in JSLE? - Observations from the UK JSLE Cohort Study. 61
33690793 2021
26
Anti-inflammatory evaluation of Scurrula ferruginea (jack) danser parasitizing on Tecoma stans (L.) H.B.K. in LPS/IFN-γ-induced RAW 264.7 macrophages. 61
33271242 2021
27
Solanum xanthocarpum fruit extract promotes chondrocyte proliferation in vitro and protects cartilage damage in collagenase induced osteoarthritic rats (Article reference number: JEP 114028). 61
33775807 2021
28
Piper sarmentosum Roxb. Attenuates Beta Amyloid (Aβ)-Induced Neurotoxicity Via the Inhibition of Amyloidogenesis and Tau Hyperphosphorylation in SH-SY5Y Cells. 61
33761853 2021
29
A narrative review of the ethnomedicinal usage of Cannabis sativa Linnaeus as traditional phytomedicine by folk medicine practitioners of Bangladesh. 61
33741060 2021
30
Kirenol, darutoside and hesperidin contribute to the anti-inflammatory and analgesic activities of Siegesbeckia pubescens makino by inhibiting COX-2 expression and inflammatory cell infiltration. 61
33152433 2021
31
Does being exposed to an educational tool influence patient preferences? The influence of an educational tool on patient preferences assessed by a discrete choice experiment. 61
33757643 2021
32
Evaluation of In Vitro Capsaicin Release and Antimicrobial Properties of Topical Pharmaceutical Formulation. 61
33804191 2021
33
New lupus criteria: a critical view. 61
33332888 2021
34
[Sjögren's syndrome: from diagnosis to treatment]. 61
33689243 2021
35
Phytochemical and biological activities of Pinus halepensis mill., and their ethnomedicinal use. 61
33276057 2021
36
Ethyl acetate extract of Tibetan medicine Rhamnella gilgitica ameliorated type II collagen-induced arthritis in rats via regulating JAK-STAT signaling pathway. 61
33223115 2021
37
Corrigendum to Health-related quality of life in gout in primary care: Baseline findings from a cohort study Seminars in Arthritis & Rheumatism, 48 (2018) 61-69. 61
33678468 2021
38
Thirty days oral Aframomum melegueta extract elicited analgesic effect but influenced cytochrome p4501BI, cardiac troponin T, testicular alfa-fetoprotein and other biomarkers in rats. 61
33096199 2021
39
Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study. 61
32613869 2021
40
22β-hydroxytingenone induces apoptosis and suppresses invasiveness of melanoma cells by inhibiting MMP-9 activity and MAPK signaling. 61
33232779 2021
41
Distal phalangeal bone erosions observed by HR-pQCT in patients with psoriatic onycholysis. 61
32885241 2021
42
The balance between clinical convenience and the new concepts of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies. 61
33725435 2021
43
Meaningful change thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis. 61
33722955 2021
44
Palindromic rheumatism: a unique and enigmatic entity with a complex relationship with rheumatoid arthritis. 61
33666522 2021
45
[Association of physical activity with fatigue and functional capacity in patients with rheumatoid arthritis]. 61
32588130 2021
46
[Analysis of perioperative blood loss of posterior lumbar interbody fusion on lumbar spondylolisthesis in patients with rheumatoid arthritis]. 61
33765720 2021
47
Profiling of Serum Oxylipins During the Earliest Stages of Rheumatoid Arthritis. 61
33001576 2021
48
Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines. 61
33617382 2021
49
Gender-Related Differences in Disease Activity and Clinical Features in Patients with Peripheral Psoriatic Arthritis: A Multi-Center Study. 61
33771757 2021
50
Joint contractures responsive to immunosuppressive therapy in a girl with childhood-onset systemic sclerosis double-seropositive for rare anti-nucleolar autoantibodies: a case report. 61
33743728 2021

Variations for Enthesopathy

Expression for Enthesopathy

Search GEO for disease gene expression data for Enthesopathy.

Pathways for Enthesopathy

Pathways related to Enthesopathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.95 SLC34A3 PTH KL FGF23
2 10.94 PTH ENPP1 ACAN
3 10.3 PTH FGF23

GO Terms for Enthesopathy

Cellular components related to Enthesopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 TNF PTH MEPE KL FGF23 ERAP1

Biological processes related to Enthesopathy according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor signaling pathway GO:0008543 9.69 KL GALNT3 FGF23
2 response to vitamin D GO:0033280 9.57 PTH PHEX
3 negative regulation of bone mineralization GO:0030502 9.56 FGF23 ENPP1
4 negative regulation of glucose import GO:0046325 9.55 TNF ENPP1
5 cellular response to vitamin D GO:0071305 9.54 PHEX FGF23
6 phosphate ion transport GO:0006817 9.52 SLC34A3 ANKH
7 cellular response to parathyroid hormone stimulus GO:0071374 9.49 PHEX FGF23
8 negative regulation of lipid storage GO:0010888 9.48 TNF CRP
9 phosphate ion homeostasis GO:0055062 9.46 PTH FGF23
10 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.43 KL FGF23
11 biomineral tissue development GO:0031214 9.43 PHEX MEPE ENPP1
12 sequestering of triglyceride GO:0030730 9.4 TNF ENPP1
13 inorganic diphosphate transport GO:0030505 9.37 ENPP1 ANKH
14 skeletal system development GO:0001501 9.35 PTH PHEX MEPE ANKH ACAN
15 regulation of bone mineralization GO:0030500 9.33 FGF23 ENPP1 ANKH
16 response to sodium phosphate GO:1904383 9.32 PHEX FGF23
17 cellular phosphate ion homeostasis GO:0030643 8.8 SLC34A3 FGF23 ENPP1

Sources for Enthesopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....